Pembrolizumab vs. chemotherapy in the first-line setting of PD-L1 ≥ 50% metastatic non-small cell lung cancer: a real-world cost-effectiveness analysis
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Liu B, Parmar A, Luo J, Dai WF, Chan KKW. Eur J Health Econ. 2025; Oct 8 [Epub ahead of print].
Antoniou T, McCormack D, Wang T, Tadrous M, Gomes T. Fundam Clin Pharmacol. 2025; 39(6):e70051.
Erman A, Everett K, Wong WWL, Forouzannia F, Greenaway C, Janjua N, Kwong JC, Sander B. PLoS One. 2025; 20(10):e0333584.
Huang YQ, Vyas MV, Bronskill SE, Li Z, Guan J, Hoang PM, Tam A, Bayley M, Vincent C, Straus SE, Watt JA. CMAJ. 2025; 197:E1067-77.
Hallet J, Rousseau M, Wakeam E, Myrehaug S, Meloche-Dumas L, Gombay A, Chan W, Singh S. JAMA Netw Open. 2025; 8(10):e2535125.
Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. Cancer Med. 2025; 14(19):e71288.
Selick A, Campitelli MA, Huang A, Balogh R, Kurdyak P, Lunsky Y. Can J Psychiatry. 2025; Sep 29.
Blanchette P, Reid J, Richard L, Shariff SZ, Raphael J, Earle CC, Garg AX, Kitchlu A. Nephrol Dial Transplant. 2025; gfaf191. Epub 2025 Sep 27.
Fu R, Sutradhar R, Li Q, Villemure-Poliquin N, Chan KKW, Karam I, Hallet J, Eskander A. JAMA Otolaryngol Head Neck Surg. 2025; Sep 25 [Epub ahead of print].
Yuan B, Kabir M, He JC, Li Y, Grant B, Narine S, Welch M, Podolsky S, Liu N, Ajaj R, Zhan LJ, Fawzy A, Xu J, Zhang Y, Yu V, Xu W, Krishnan RG, Gallinger S, Chan KKW, Krzyzanowska MK, Truong T, Liu G, Grant RC. JCO Clin Cancer Inform. 2025; 9:e2500073. Epub 2025 Sep 25.